Isatuximab-irfc Injection
Isatuximab-irfc injection is used along with pomalidomide (Pomalyst) and dexamethasone to treat multiple myeloma (a type of cancer of the bone marrow) in adults who have received at least two other medications, including lenalidomide (Revlimid) and a proteasome inhibitor such as bortezomib (Velcade) or carfilzomib (Kyprolis). It is also used along with carfilzomib (Kyprolis) and dexamethasone to treat multiple myeloma in adults whose cancer has returned or is unresponsive to at least one other treatment. Isatuximab-irfc injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells.
🔔 How should this medicine be used?
Isatuximab-irfc injection comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse. Initially, it is usually given on days 1, 8, 15, and 22 of the first 28-day cycle. After the first cycle, it is usually given on days 1 and 15 of 28-day cycle. This cycle may be repeated as long as the medication continues to work and does not cause severe side effects.
A doctor or nurse will watch you closely while you are receiving the infusion and after the infusion to be sure you are not having a serious reaction to the medication. You will be given other medications to help prevent reactions to isatuximab-irfc. Tell your doctor or nurse immediately if you experience any of the following symptoms that may occur during the infusion or for up to 24 hours after you receive the infusion: nausea; shortness of breath; wheezing; difficulty breathing; swelling of the face, mouth, throat, or tongue; throat tightness; dizziness; lightheadedness; fainting; runny or stuffy nose; nasal congestion; cough; or chills.
Your doctor may permanently or temporarily stop your treatment. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with isatuximab-irfc.
Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.
